Press Releases.

Investor Menu

Investor Relations

Overview
News
Press Releases Publications
Investor Presentation & Events
Presentations Events
Governance
Directors Leadership Scientific Advisory Board Manufacturing and Quality Advisory Board Committee Composition Documents & Charters
Stock Information
Stock Quote & Chart Analyst Coverage Ownership Profile
Financials & Filings
SEC Filings Annual Reports and Proxies Quarterly Results
Investor Resources
Fireside Chat Platform Investor FAQs Email Alerts Contact IR

Search

Year

March 08, 2023

PDF Version

Vaxart to Host Full Year 2022 Business Update and Financial Results Conference Call on March 15

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. , March 08, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the full year ended December 31, 2022 after the market close on Wednesday, March

February 14, 2023

PDF Version

Vaxart Doses First Subject in the Phase 2 Clinical Trial of its Bivalent Norovirus Candidate

Study to evaluate safety and immunogenicity of oral norovirus vaccine in healthy adults SOUTH SAN FRANCISCO, Calif. , Feb. 14, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced that it has dosed the first subject in the Phase 2 clinical trial of its oral tablet bivalent norovirus

Pagination

First page
Previous page
Page 1
Page 2
Current page 3

Welcome
Tech
Mission
Investors

Terms of Use
Privacy Policy

LinkedIn
Twitter
Youtube

Scroll to top